亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費(fèi)注冊|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

隨州市紅旗化工有限公司  

醫(yī)藥原料醫(yī)藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 維替泊芬 CAS號: 129497-78-5
維替泊芬 CAS號: 129497-78-5
單價 面議對比
詢價 暫無
發(fā)貨 湖北隨州市付款后3天內(nèi)
型號 129497-78-5
過期 長期有效
更新 2020-06-18 10:08
 
詳細(xì)信息
 維替泊芬
CAS號: 129497-78-5
英文名稱: Verteporfin
英文同義詞: VERTEPORFIN (200 MG);trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid 3,4,9-trimethyl ester;Verteporfin
分子式: 2C41H42N4O8
分子量: 1437.61
標(biāo)準(zhǔn):USP32
含量:≥98.5% 
性狀:深綠色疏松塊狀物。
用途:適用于繼發(fā)于年齡相關(guān)的眼部新生血管形成的患者,以及病理性近視或眼組織胞漿菌病
包裝:25kg/桶
©2025 隨州市紅旗化工有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:31230  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |